The Centre for Osteoarthritis Pathogenesis Versus Arthritis aims to develop new treatments for this disabling condition, improving healthcare and transforming people's lives.
Our strategy is to turn our research findings into patient benefit. This includes finding targets for new treatments, new tests or markers, and personalised approaches to symptom management for osteoarthritis.
Directed by Professor Tonia Vincent within the Kennedy Institute of Rheumatology, the OA Centre is hosted by the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford.
We bring together researchers and clinicians from across the University of Oxford including the Kennedy Institute of Rheumatology, the Botnar Research Centre, and the Nuffield Orthopaedic Centre, as well as Queen Mary University of London.
In addition to developing novel disease "markers" and therapies for patients with osteoarthritis, we are also creating a national training resource for scientists and clinicians working within the OA field.
The Centre was created in April 2013 with substantial funding from Versus Arthritis, the University of Oxford and the Kennedy Trust for Rheumatology Research (KTRR). A further five years funding was awarded in 2018.
Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, placebo-controlled, feasibility study.
Williams JAE. et al, (2022), Lancet Rheumatol, 4, e725 - e737
Clinical and molecular associations with outcomes at two years after acute knee injury: a longitudinal study in the Knee Injury Cohort at the Kennedy (KICK)
Garriga C. et al, (2021), Lancet Rheumatology
Of mice and men: converging on a common molecular understanding of osteoarthritis.
Vincent TL., (2020), Lancet Rheumatol, 2, e633 - e645
TSG-6 Is Weakly Chondroprotective in Murine OA but Does not Account for FGF2-Mediated Joint Protection.
Zhu L. et al, (2020), ACR Open Rheumatol, 2, 605 - 615
Does pain at an earlier stage of chondropathy protect female mice from structural progression after surgically induced osteoarthritis?
von Loga IS. et al, (2020), Arthritis Rheumatol
The molecular profile of synovial fluid changes upon joint distraction and is associated with clinical response in knee osteoarthritis.
Watt FE. et al, (2020), Osteoarthritis Cartilage, 28, 324 - 333
Mechanoflammation in osteoarthritis pathogenesis.
Vincent TL., (2019), Semin Arthritis Rheum, 49, S36 - S38
Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis.
von Loga IS. et al, (2019), Ann Rheum Dis, 78, 672 - 675
New drug offers hope for people with hand osteoarthritis
22 December 2022
A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.
Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age
15 October 2021
A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.
Exploring the link between joint injury and osteoarthritis
25 June 2021
A new study published in The Lancet Rheumatology shows potential ways to predict how likely someone is to develop osteoarthritis after a knee injury.
Vaccine developed to treat osteoarthritic pain
12 March 2019
Researchers have developed a vaccine that blocks the effects of the main cause of pain in osteoarthritis (OA) - nerve growth factor (NGF) - in mice.
Preventing osteoarthritis after injury: first international pre-guidelines
18 September 2018
International expert working group develop first pre-guidelines for conducting robust studies aimed at prevention of osteoarthritis (OA) after acute knee injury.
Cutting Edge OA Meeting
Cutting Edge Osteoarthritis is a focused meeting with an exciting programme of internationally renowned speakers presenting the cutting edge of osteoarthritis research. The first meeting was in 2015 and it runs every two years.